YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM

摘要：在过去的十年里，随着多种癌症的出现，治疗方法发生了戏剧性的变化 在佐剂和转移性肿瘤中诱导反应和延长生存期的免疫调节疗法 设置。现在很明显，这些进展只是一个快速发展的领域的先锋。调查人员 在免疫学的临床前和临床进展中发挥了关键作用。 肿瘤学。持续的进步需要更好地了解主抗病和继发抗病 免疫治疗，肿瘤微环境中免疫抑制的生物学，合理的药物组合， 药物毒性研究和针对免疫疗法的新试验设计。因此，迫切需要 培训初级研究人员进行以患者为中心的癌症免疫学和免疫疗法研究，以进一步 加快这些进步。我们的免疫肿瘤学培训计划(IOTP)通过以下方式满足这一关键需求 对医学博士或医学博士研究生进行临床相关免疫肿瘤学和翻译免疫学方面的培训。至少 在任何给定的时间，都有五名初级教师学者入学。IOTP与耶鲁现有的培训计划不同 因为它是唯一一个专门专注于以患者为导向的免疫学研究的初级教员培训的机构。 肿瘤学和免疫疗法。到目前为止，IOTP在开发多样化的 独立资助的研究人员，他们利用我们机构在免疫生物学方面的丰富专业知识 和免疫疗法。IOTP的教职员工有广泛的指导记录，并积极从事研究 在这些地区。IOTP由耶鲁大学癌症中心(YCC)支持，并与耶鲁大学中心为 临床研究，是我们CTSA奖助金的来源，提供了一些基础课程。关键字识别 功能或IOTP是专门为该计划开发的教学性和实践性培训，包括 基础免疫学和癌症免疫学，免疫治疗特异性临床试验设计，癌症免疫学 论坛和一个单独定制的为期两年的翻译免疫肿瘤学研究项目，该项目包括 实验室和/或临床研究。下一个资助期的新内容包括一门计算课程 免疫学，努力培训导师和社区外展和参与倡议。每个人 SCHOLAR有一个导师小组。在耶鲁医学院任职五年内的初级教员是 符合条件的，任何时候最多任命五名学者，另外一名学者将由YCC资助。这个 该计划由一个执行委员会领导，执行委员会由PI(YCC副癌症中心Harriet Kluger博士)组成 教育和培训主任)，联席主任，Diane Krause博士，医学博士，细胞专家 治疗，大卫·斯特恩博士，课程发展主席，罗伊·赫布斯特，医学博士，肿瘤学主任 癌症中心转化性研究副主任。总而言之，IOTP利用了以下领域 深厚的机构实力，使YCC能够专注于跨学科的学者培训 癌症免疫治疗以满足日益增长的癌症免疫学专家和研究人员的需求。

Summary: Therapy for multiple types of cancer has evolved dramatically in the last decade with the emergence of immune modulation therapies that induce responses and prolong survival in the adjuvant and metastatic settings. It is now apparent that these advances are only the vanguard in a rapidly evolving field. Investigators from Yale School of Medicine have played key roles in both pre-clinical and clinical advances in immuno- oncology. Continued advancement requires better understanding of primary and secondary resistance to immune therapy, the biology of immune suppression in the tumor microenvironment, rational drug combinations, studies of drug toxicities and new trial designs specific for immune therapies. Hence, there is an urgent need to train junior investigators to conduct patient-oriented cancer immunology and immunotherapy studies to further accelerate these advances. Our Immuno-Oncology Training Program (IOTP) addresses this critical need by training MD or MD/PhD Scholars in clinically-relevant immuno-oncology and translational immunology. At least five junior faculty scholars are enrolled at any given time. IOTP is distinct from existing training programs at Yale as it is the only one to specifically focus on training of junior faculty in patient-oriented research in immuno- oncology and immunotherapy. IOTP has been highly successful to date in developing a diverse pool of independently funded researchers who capitalize on the wealth of expertise at our institution in immunobiology and immunotherapy. IOTP faculty have extensive track records of mentorship and are actively pursuing research in these areas. IOTP is supported by the Yale Cancer Center (YCC) and synergizes with the Yale Center for Clinical Investigation, home to our CTSA grant, which provides some foundational courses. Key distinguishing features or IOTP are didactic and practical training developed specifically for this program including courses on basic immunology and cancer immunology, immunotherapy-specific clinical trial design, the Cancer Immunology Forum and an individually tailored, two-year Translational Immuno-oncology research project encompassing laboratory and/or clinical research. New for the next funding period include a course on computational immunology, endeavors for training in mentorship and community outreach and engagement initiatives. Each scholar has a panel of mentors. Junior faculty within five years of appointment at Yale School of Medicine are eligible, with up to five scholars appointed at any one time, and an additional scholar will be funded by YCC. The program is led by an Executive Committee comprised of the PI (Dr. Harriet Kluger, YCC Associate Cancer Center Director for Education and Training), the Co-Director, Dr. Diane Krause, MD, PhD, an expert on cellular therapies, David Stern, PhD, Chair for Curriculum Development and Roy Herbst, MD, PhD, Chief of Oncology and Associate Cancer Center Director for Translational Research. In summary, the IOTP draws upon an area of profound institutional strength and enables YCC to focus specifically on cross-disciplinary training of scholars in Cancer Immunotherapy to meet the increasing need for cancer immunology experts and researchers.